Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $247.32 million. The enterprise value is $243.14 million.
| Market Cap | 247.32M |
| Enterprise Value | 243.14M |
Important Dates
The last earnings date was Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 209.60 million shares outstanding. The number of shares has increased by 10.93% in one year.
| Shares Outstanding | 209.60M |
| Shares Change (YoY) | +10.93% |
| Shares Change (QoQ) | +7.91% |
| Owned by Insiders (%) | 1.91% |
| Owned by Institutions (%) | 25.27% |
| Float | 190.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.32 |
| Forward PS | 1.30 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.30 |
| EV / EBITDA | 33.11 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.70
| Current Ratio | 1.70 |
| Quick Ratio | 1.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | 5.15 |
| Debt / FCF | n/a |
| Interest Coverage | -5.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -18.00% |
| Return on Capital (ROIC) | -300.73% |
| Revenue Per Employee | $1.12M |
| Profits Per Employee | -$257,677 |
| Employee Count | 167 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.84 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.26% in the last 52 weeks. The beta is 0.93, so AKBA's price volatility has been similar to the market average.
| Beta (1Y) | 0.93 |
| 52-Week Price Change | +8.26% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 1.32 |
| Relative Strength Index (RSI) | 37.32 |
| Average Volume (30 Days) | 5,201,231 |
Short Selling Information
The latest short interest is 11.86 million, so 5.66% of the outstanding shares have been sold short.
| Short Interest | 11.86M |
| Short Previous Month | 13.69M |
| Short % of Shares Out | 5.66% |
| Short % of Float | 6.23% |
| Short Ratio (days to cover) | 2.76 |
Income Statement
In the last 12 months, AKBA had revenue of $187.23 million and -$43.03 million in losses. Loss per share was -$0.23.
| Revenue | 187.23M |
| Gross Profit | 121.66M |
| Operating Income | -31.65M |
| Pretax Income | -43.03M |
| Net Income | -43.03M |
| EBITDA | 7.34M |
| EBIT | -36.06M |
| Loss Per Share | -$0.23 |
Balance Sheet
The company has $41.96 million in cash and $37.78 million in debt, giving a net cash position of $4.18 million or $0.02 per share.
| Cash & Cash Equivalents | 41.96M |
| Total Debt | 37.78M |
| Net Cash | 4.18M |
| Net Cash Per Share | $0.02 |
| Equity / Book Value | -27.26M |
| Book Value Per Share | -0.13 |
| Working Capital | 46.46M |
Cash Flow
| Operating Cash Flow | -25.28M |
| Capital Expenditures | n/a |
| Free Cash Flow | -25.28M |
| FCF Per Share | -$0.12 |
Margins
Gross margin is 64.98%, with operating and profit margins of -16.90% and -22.98%.
| Gross Margin | 64.98% |
| Operating Margin | -16.90% |
| Pretax Margin | -22.98% |
| Profit Margin | -22.98% |
| EBITDA Margin | 3.92% |
| EBIT Margin | -19.26% |
| FCF Margin | -13.50% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.93% |
| Shareholder Yield | -10.93% |
| Earnings Yield | -17.40% |
| FCF Yield | -10.22% |
Analyst Forecast
The average price target for AKBA is $4.67, which is 295.76% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.67 |
| Price Target Difference | 295.76% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 18.42% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -8.96 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.96 |
| Piotroski F-Score | 4 |